PURPOSE: To obtain a therapeutic agent for Parkinson's disease or a motion regulator for patients suffered from Parkinson's disease. CONSTITUTION: This therapeutic agent or motion regulator contains, as active ingredient, a sulfonylurea-based adenosine triphosphate-sensitive potassium canal blocker (e.g. tolbutamide, i.e., N-[(butylamino)carbonyl)]-4-methyl benzenesulfonamide; glyburide, i.e., 1- [p-2-(5-chloro-o-anisamido) ethyl]phenyl}sulfonyl-3-cyclohexylurea; glipizide, i.e., 1-cyclohexyl-3- [p-(2-(5- methyl-pyrazinecarboxamido)ethyl]phenyl}sulfonylurea). This invention also includes a therapeutic agent for Parkinson's disease with quinine as blocker.
THERAPEUTIC AGENT FOR PERKINSON'S DISEASE